Pfizer agreed to a $50 million settlement to resolve a class-action antitrust lawsuit initiated in 2020 that alleged the corporate and companion Mylan conspired with Teva to delay the introduction of a generic model of EpiPen.
The plaintiffs claimed Mylan had struck a cope with Teva to delay the introduction of a generic model of Teva’s branded drug in alternate for Teva delaying a generic model of EpiPen. The consequence was direct purchasers paid greater than if Teva’s generic epinephrine auto-injector had entered the market.
This settlement follows an settlement in 2021 during which Pfizer agreed to a $345 million fee to settle an antitrust swimsuit initiated in 2017 by oblique purchasers comparable to insurers, customers, and pension funds. That swimsuit additionally alleged anti-competitive actions relating to EpiPen.
Mylan, now a subsidiary of Viatris, agreed in 2017 to a $465 million settlement to resolve claims that it had overcharged Medicaid for EpiPen by falsely classifying the gadget as a generic. In March of the next yr, Viatris paid $264 million to settle a class-action swimsuit introduced by customers and third-party payers who alleged antitrust conduct associated to EpiPen.
Who’re the winners? Not you.
Mylan, Pfizer, and Teva paid out only a fraction of the beneficial properties they made because of their anti-competitive conduct, and regulation corporations sometimes preserve one-third of the judgments they win.
As typical, the allergic group bore the brunt of the EpiPen shenanigans. The query is, how many individuals died or have been significantly injured over the interval as a result of they couldn’t afford epinephrine auto-injectors when anaphylaxis struck?